Biological drugs (sometimes known as "biologics" or "originators") are a type of medication that is derived primarily from biological sources. They are one of the most expensive drugs on the market due to their high cost and difficulty in development. Biosimilar drugs are similar to biologic medicines, but they are not an exact reproduction of the biologic and cannot be labelled a “generic” because of the natural variability involved in their development. The introduction of biosimilars was supposed to shake up the pharmaceutical industry, resulting in reduced prices and greater access to drugs. Market access, on the other hand, has been slower than many expected, with some claiming anti-competitive activities as a barrier to entry and expansion.
- Barriers in Developing Biosimilar Drugs
- Global trends in Biosimilar Drug Market
- Regulatory Constraints
A C Matin
Stanford University, United States
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Luis Jesus Villarreal Gomez
Autonomous University of Baja California, Mexico
John K Maesaka
NYU Langone Hospital Long Island, United States
Richard Denk
SKAN AG, Switzerland
Peter B Chase
Essentia Health- St. Mary's Medical Center, United States
Saliha Koc Aslan
Acibadem Healthcare Group, Turkey
Ana Isabel Rocha Faustino
University of Evora, Portugal
Narapereddy Krishna Prasad
Reckitt Benckiser LLC, United States
Title : Extracellular vesicles as delivery vehicles of therapeutic compounds
Stefania Raimondo, University of Palermo, Italy
Title : EU GMP annex1 barrier system and PIC/s annex 2A on cell and gene therapy
Richard Denk, SKAN AG, Switzerland
Title : Role of nanoformulations in treating Cystic Fibrosis
Bhupendra Gopalbhai Prajapati, Ganpat University, India
Title : Dual GIP/GLP-1 receptor stimulation in treatment of type 2 diabetes mellitus – The ground-breaking 'twincretin' approach
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Pathology and patient safety: The vital role of electronic medical record and pathology informatics in error reduction and precision medicine
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : mRNA-based systemically delivered directed gene therapy using nanomaterials
A C Matin, Stanford University, United States
Title : Colon-specific scallop hydrolysates/Κ-carrageenan hydrogel loaded with curcumin alleviates dss-induced colitis through modulation of inflammatory cytokines and gut microbiota
Hai Tao Wu, Dalian Polytechnic University, China
Title : Mucoadhesive electrospun fibrous systems for the fast and sustained delivery of drugs
Luis Jesus Villarreal Gomez, Autonomous University of Baja California, Mexico
Title : General and local anaesthetic agents: An analysis of their safety data
Francesca Gargano, Campus Bio-Medico University of Rome, Italy
Title : 15,16-dihydrotanshinone-I-laden PLGA-co-PEG nanoparticles are potential therapeutic agents for the treatment of colorectal cancer by targeting the β-catenin/CD36 axis
Kwan Hiu Yee, Hong Kong Baptist University, China